Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbidopa, Levodopa and Entacapone Tablets.".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the USFDA (US Food and Drug Administration) for its generic version of Carbidopa, Levodopa and Entacapone Tablets. This medication is commonly used in the treatment of Parkinson's disease. The approval allows Alembic to manufacture and sell this product in the highly lucrative US generic pharmaceutical market. USFDA approvals are a key revenue driver for Indian pharma companies with significant US operations. This adds to Alembic's portfolio of approved generic products in the US.
Positive for the company as the approval opens up additional revenue from US generic sales, strengthening Alembic's US business segment. May support stock sentiment in the short term, though actual revenue impact depends on market share captured.